Navigation Links
First Coast Oncology to Offer Next Generation Proton Therapy
Date:9/17/2008

First Coast Oncology to be the first private practice in the Southeast to

offer state-of-the-art proton radiation therapy

JACKSONVILLE, Fla., Sept. 17 /PRNewswire/ -- Scot Ackerman, M.D., Medical Director, First Coast Oncology, Jacksonville, FL is pleased to announce the recent agreement for the placement of the Monarch250(TM) Proton Therapy System from Still River Systems, Inc, in Jacksonville, Florida.

First Coast Oncology will become the first private practice in the Southeast to add this state-of-the-art treatment modality to its comprehensive cancer center. The Monarch250, a unique compact system, will provide the same precise, non-invasive treatment advantages and capabilities as larger commercially available systems but at a reduced cost. Still River Systems and the Massachusetts Institute of Technology have used advanced superconducting technology to develop the Monarch250 and make proton therapy treatments more practical for freestanding cancer centers and hospitals alike.

"We are excited to have the opportunity to develop with First Coast Oncology, the ability to enhance and expand their cancer treatment capabilities," said Marc Buntaine, CEO of Still River Systems. "The Monarch250 will answer the strong demand from the patient and clinical community for a precise, versatile and affordable proton therapy device."(1)

Proton therapy can deliver with high precision, a burst of radiation to malignant tissue while sparing the adjacent normal tissue, which can result in fewer side effects. Due to the high demand for proton therapy, larger proton centers are operating at capacity and are unable to meet the demand for treatment. First Coast Oncology's new proton therapy acquisition will not only provide patients in Jacksonville with additional access to highly beneficial proton therapy treatment, but also provide treatment to patients in Georgia, Alabama, South Carolina and North Carolina.

"First Coast Oncology is committed to being on the cutting edge of technology," said Scot Ackerman, Medical Director of First Coast Oncology. "This strategic agreement ensures that our patient community will have greater availability to the latest cancer fighting technology."

Installation of the Monarch250 is expected to commence in early 2011 at First Coast Oncology's Mandarin location at 10881 San Jose Boulevard.

About First Coast Oncology

The staff of First Coast Oncology consists of board-certified radiation oncologists and medical physicists, certified medical dosimetrists, a nuclear medicine technologist, oncology certified nurses, oncology social workers, and radiation therapists.

We offer convenient care at our state-of-the-art facilities throughout Northeast Florida. Our locations at St. Vincent's Medical Center, Mandarin and at Baptist Medical Center -- Nassau, offer the most advanced medical equipment and technology.

Our practice is dedicated to advancing the understanding, treatment, and prevention of cancer through research, advocacy, and community service. For more information, call 904-224-0667 or visit http://www.firstcoastoncology.com.

Contact:

Kathy Garrett

Communications Director, First Coast Oncology

Kathy@firstcoastoncology.com

904-224-0667

(1) About Still River Systems Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients access to high quality, cost-effective proton therapy solutions, and to help establish this superior treatment modality as a standard of care for patients worldwide. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. This system has not yet been cleared by the FDA for commercial use in clinical therapy. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit their website at http://www.StillRiverSystems.com.

Contact:

Melanie M. Miller

Marketing & Communications Coordinator, Still River Systems

mmiller@stillriversystems.com

978-540-1500


'/>"/>
SOURCE Still River Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MIGENIX Reports First Quarter Fiscal 2009 Financial Results
2. First 3-D processor runs at 1.4 Ghz on new architecture
3. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
4. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
5. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
6. Abeome Forms First Class Scientific Advisory Board
7. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
10. Therapure Biopharma Inc. opens for business with first client contracts
11. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):